An official website of the United States government Here’s how you know

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

In this section: Drugs

DDT COA #000027: A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF)

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Drug Evaluation (ODE) II
Division of Pulmonary, Allergy, and Rheumatology Products (DPARP)

DDT COA Number
DDT COA #000027

Instrument Name
A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF)

Disease/Condition
Idiopathic pulmonary fibrosis (IPF)

Concept of Interest
Symptom experience, daily functioning and other health-related quality of life impacts

Context of Use
Adult patients (>18 years) with IPF

COA Type
PRO

Qualification Stage
In transition to 507 process

Requestor(s)
National Jewish Health

Contact(s)
Jeff Swigris

Date Accepted into CDER’s COA Qualification Program
January 25, 2012

Back to Clinical Outcome Assessments (COA) Qualification Submission

Top